GlassScriptPhysician profile
Joseph Prah
NPI 1689787731
$5,033.70
in general payments reported to CMS, 2019-2025
41 companies · $1,291 in 2025
The $1,291 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $16.14 · 2021: $135 · 2022: $572 · 2023: $1,328 · 2024: $1,581 · 2025: $1,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,564 · Education: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,564.24 |
| Education | $636.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $611.77 | 2022-2025 | |
| Janssen Biotech, INC. | $373.06 | 2024-2025 | Rybrevant, Erleada, Akeega |
| Astellas Pharma US INC | $329.69 | 2019-2024 | Padcev, Xtandi |
| Regeneron Healthcare Solutions, INC. | $292.93 | 2022-2025 | Libtayo, Lynozyfic |
| Incyte Corporation | $272.26 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $264.25 | 2020-2025 | Opdivo, Opdualag |
| Pfizer INC. | $228.95 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $217.94 | 2022-2025 | Ninlaro, Fruzaqla, Alunbrig |
| Eisai INC. | $204.22 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $200.68 | 2022-2025 | Zepzelca |
| Abbvie INC. | $200.57 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $142.88 | 2022-2025 | Keytruda, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $141.26 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $140.96 | 2023-2025 | Imfinzi |
| Aveo Pharmaceuticals, INC. | $134.91 | 2024-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $116.47 | 2023-2024 | Enhertu |
| Sanofi-Aventis U.S. LLC | $99.95 | 2022 | |
| Array Biopharma INC | $99.33 | 2022-2025 | Mektovi, Lorbrena, Braftovi |
| Seagen INC. | $94.29 | 2021 | |
| Genzyme Corporation | $85.53 | 2021-2025 | |
| Lilly USA, LLC | $78.93 | 2022-2025 | Jaypirca, Verzenio |
| Genentech USA, INC. | $77.48 | 2021-2024 | Venclexta, Tecentriq |
| Taiho Oncology, INC. | $67.40 | 2024-2025 | |
| Amgen INC. | $61.04 | 2023 | Lumakras |
| Glaxosmithkline, LLC. | $59.63 | 2023 | Jemperli, Zejula |
| Gilead Sciences, INC. | $50.25 | 2021-2024 | |
| Celgene Corporation | $44.41 | 2019 | |
| Foundation Medicine, INC. | $43.35 | 2023 | |
| Stemline Therapeutics INC. | $39.34 | 2023-2024 | Orserdu |
| Coherus Oncology, INC. | $32.04 | 2024 | |
| Novocure INC. | $31.80 | 2024-2025 | Optune, Optune Lua (Novottf-200t) |
| Genmab U.S., INC. | $25.85 | 2024 | Tivdak |
| Progenics Pharmaceuticals, INC. | $25.62 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $23.47 | 2024 | Somatuline Depot, Onivyde |
| Pharmaessentia USA Corporation | $22.92 | 2023 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.82 | 2024 | Gilotrif |
| Geron Corporation | $17.99 | 2025 | Rytelo |
| Pharmacyclics LLC, An Abbvie Company | $16.59 | 2023 | Epkinly |
| Adc Therapeutics America, INC. | $15.41 | 2023 | |
| Kite Pharma, INC. | $14.34 | 2023 | Yescarta |
| Puma Biotechnology, INC. | $14.12 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Prah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.